Fremantle-based biotech SeaStock has opened its Series A funding round, seeking capital to accelerate its proprietary algae-derived compounds.

Fremantle-based biotech SeaStock has opened its Series A funding round, seeking capital to accelerate its proprietary algae-derived compounds.